Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 195Neoplasm Metastasis 22Prostatic Neoplasms, Castration-Resistant 20Breast Neoplasms 19Neoplasms 18Metastatic Castration Resistant Prostate Cancer 10Prostate Cancer Metastatic 7Metastatic Castration-Resistant Prostate Cancer 7Triple Negative Breast Neoplasms 6Metastatic Castration-resistant Prostate Cancer 6Parkinson Disease 4, Autosomal Dominant Lewy Body 5Pancreatic Neoplasms 5Colorectal Neoplasms 5Castration-resistant Prostate Cancer 5Carcinoma, Non-Small-Cell Lung 5Melanoma 4Carcinoma, Hepatocellular 4Bulbo-Spinal Atrophy, X-Linked 4Adenocarcinoma 4Urinary Bladder Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Small Cell Lung Carcinoma 3Prostate Adenocarcinoma 3Ovarian Neoplasms 3Carcinoma, Renal Cell 3mCRPC 2Uterine Cervical Neoplasms 2Recurrence 2Prostatic Diseases 2Non-metastatic Castration-resistant Prostate Cancer 2

Interventions

enzalutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
MCRPC × enzalutamide × Clear all
NCT03851640 2025-03-12

A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC).

Hinova Pharmaceuticals Inc.

Phase 3 Recruiting
417 enrolled

MCRPC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡